Streptokinase-A Drug for Thrombolytic Therapy: A Patent Review

Adinarayana Kunamneni, Ravi Durvasula

Research output: Contribution to journalReview articlepeer-review


Accumulation of fibrin in blood vessels significantly increases thrombosis, leading to myocardial infraction and other cardiovascular diseases. Microbial enzymes are one option for curing this pathological condition. Fibrinolytic enzymes such as urokinase (UK), tissue type plasminogen activator (t-PA) and streptokinase (SK) attracted much attention for thrombolytic therapy. Among them SK is preferable in low-resource settings because it is cost-effective. Therefore, the purpose of this review is to summarize recent patents related to the occurrence, mechanism of action, physico-chemical properties, cloning and expression, production, structure, immunogenicity, chemical modification, in vivo application and clinical trials of SK. This patent review considers the properties and characteristics of SK that make it a preferred agent for thrombolytic therapy.

Original languageEnglish (US)
Pages (from-to)106-121
Number of pages16
JournalRecent Patents on Cardiovascular Drug Discovery
Issue number2
StatePublished - 2014

ASJC Scopus subject areas

  • Drug Discovery
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Streptokinase-A Drug for Thrombolytic Therapy: A Patent Review'. Together they form a unique fingerprint.

Cite this